CiToxLAB increases capabilities in reprotoxicology and juvenile studies

Appoints Paul Barrow as director of scientific projects and client consulting

CiToxLAB, a French contract research organisation (CRO) involved in non-clinical research, has appointed Paul Barrow as director of scientific projects and client consulting.

Barrow has more than 30 years’ experience in preclinical safety testing, gained through working for the pharmaceutical industry and CROs in France, the UK and Italy.

Most recently Barrow was a director of toxicology at Ricerca Biosciences. In more than 10 years at Ricerca, he collaborated with more than 100 clients from the pharmaceutical, biotech, chemical and food industries to devise and execute non-clinical regulatory submission packages and to address pre- and post-marketing safety issues.

Barrow is a member of the Society of Toxicology, the Teratology Society, the European Teratology Society, Eurotox and is a European Registered Toxicologist.

You may also like

Research & Development

CiToxLAB expands inhalation test capabilities in North America and Europe

Opens rodent and non-rodent facility in Canada and will double rodent capacity in Hungary
Regulatory

CiToxLAB emerges from CIT and LAB Research merger

Will provide pre-clinical and specialist services from four facilities
Regulatory

CIT acquires assets of LAB Research Inc

This acquisition makes the new group one of the world’s top preclinical CROs
Research & Development

CIT to purchase LAB Research

Acquisition will take Canadian CRO out of receivership
Research & Development

Scientists develop new technique to fight antimicrobial resistance

The team of researchers from the University of Leicester have developed a new technique to sequence phage genomes from individual plaques and hopes to use it to build fully characterised libraries of bacteriophages, expanding the number of candidates available to tackle drug-resistant infections
Research & Development

Lancet Oncology Commission launches to examine future of academic cancer clinical trials amid funding and regulatory pressures

A global coalition of clinical investigators and patient representatives has launched the Lancet Oncology Commission to address the value and challenges of independent academic cancer clinical trials, amid growing concerns over regulatory complexity, limited public funding and the need for new international collaboration models
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

UK clinical trial reforms come into force in largest regulatory overhaul in 20 years

The MHRA and Health Research Authority are implementing the most significant package of clinical trial regulatory reforms in more than two decades, introducing faster assessment routes for lower-risk trials and mandatory registration of trial results
Subscribe now